Colorectal cancer patients with liver metastases and severe hyperbilirubinemia: A consecutive series that explores the benefits and risks of chemotherapy

Tamana Walia, J. Fernando Quevedo, Timothy J. Hobday, Gary Croghan, Aminah Jatoi

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Background: Do colorectal cancer patients with hyperbilirubinemia and liver metastases benefit from chemotherapy? Methods/Results: This study entailed a review of 3,019 consecutive patients with colorectal cancer. Within this cohort, 20 met the study's a priori selection criteria, which included a new diagnosis of colorectal cancer, no prior therapy, and a total bilirubin of ≥3.0 mg/ dL. All 20 patients had liver metastases, and as a whole the group had a median serum bilirubin of 6.4 mg/dL (range 3.1, 28 mg/dL). Six patients received chemotherapy with an oxaliplatin-containing regimen, and four subsequently sustained a drop in their bilirubin. In one instance, a drop from 27.2 to 2.5 mg/dL occurred. These six patients lived a median of 71 days (range 23+, 283 days), but one treatment-related death occurred. In contrast, patients who received only supportive care lived a median of 28 days. Conclusion: Chemotherapy appears to provide modest benefit to newly diagnosed colorectal cancer patients with severe hyperbilirubinemia.

Original languageEnglish (US)
Pages (from-to)1363-1366
Number of pages4
JournalTherapeutics and Clinical Risk Management
Volume4
Issue number6
StatePublished - Dec 1 2008

Keywords

  • Chemotherapy
  • Colorectal cancer
  • Hyperbilirubinemia
  • Liver metastases
  • Oxaliplatin

ASJC Scopus subject areas

  • Safety Research
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)
  • Chemical Health and Safety

Fingerprint Dive into the research topics of 'Colorectal cancer patients with liver metastases and severe hyperbilirubinemia: A consecutive series that explores the benefits and risks of chemotherapy'. Together they form a unique fingerprint.

  • Cite this